Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

BACKGROUND: Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity of the first Bruton’s kinase (Btk) and spleen tyrosine kinase (Syk) inhibitors, a small fracti...

Descripción completa

Detalles Bibliográficos
Autores principales: Balsas, P., Esteve-Arenys, A., Roldán, J., Jiménez, L., Rodríguez, V., Valero, J. G., Chamorro-Jorganes, A., de la Bellacasa, R. Puig, Teixidó, J., Matas-Céspedes, A., Moros, A., Martínez, A., Campo, E., Sáez-Borderías, A., Borrell, J. I., Pérez-Galán, P., Colomer, D., Roué, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374673/
https://www.ncbi.nlm.nih.gov/pubmed/28359287
http://dx.doi.org/10.1186/s13045-017-0447-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374673/
https://www.ncbi.nlm.nih.gov/pubmed/28359287
http://dx.doi.org/10.1186/s13045-017-0447-6

Ejemplares similares